Paxlovid Rebound Proven in Prospective Study
By Peter A. McCullough, MD, MPH The US Centers for Disease Control placed a public health advisory on Pfizer’s flagship oral COVID-19 drug, Paxlovid on May 24, 2022 based a a few case reports of viral rebound. A new prospective randomized trial by Yang and colleagues confirmed shockingly high rates of virologic 21.1% and symptomatic […]
Discuss on Nostr!
Nostr Note ID note1hx8pf7nhj5fzhhcxfftfqe3uq9x9nd0mrphkstjjw2xendnn9wusqcuuxf Open on Primal.net Open on Snort.social Open on Iris.to Open on Coracle.social
New to Nostr?
Create an account now & join the conversation!
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.